



Stef Heylen, M.D.

**Managing Director Janssen
Pharmaceutica**

**Chief Operating Officer
Development
Janssen Research &
Development**

Stef Heylen, MD, is Chairman of the Board of Directors, Chairman of the Management Board of Janssen Pharmaceutica NV, Belgium, and Chief Operating Officer, Development, Janssen R&D globally.

Stef is a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee, member of the Janssen R&D Senior Leadership Team, the Janssen R&D Development Committee and the Janssen R&D Investment Committee. Stef brings over 30 years of drug development and executive management experience to his role with the company. His expertise extends over a wide range of areas: the development of small molecules, monoclonal antibodies, vaccines, clinical research in neuroscience and infectious diseases, regulatory affairs, drug safety, medical affairs, operations, project/portfolio and general management.

As Managing Director Stef oversees the corporate direction and strategy of Janssen Pharmaceutica NV, focusing on leadership, driving innovation and cross-functional collaboration to address the unmet medical needs for patients in the development of tomorrow's solutions. He is responsible for maximizing existing strengths and leveraging the present blend of innovation and experience to break new ground.

As Chief Operating Officer, Development, and Global Leader of Janssen Development Management, Operations and Analytics, Stef oversees the development process overall as well as essential analytical capabilities (portfolio, statistics, clinical operations) and is accountable for operationalizing and managing the Janssen R&D extensive development portfolio.

In his previous role, Stef served with the Johnson & Johnson Innovation Program Office supporting the Johnson & Johnson Chief Scientific Officer in driving meaningful innovation and leveraging innovation capabilities across all sectors of the enterprise.

He was Head of R&D and Chief Medical Officer for Janssen Alzheimer Immunotherapy, LLC, based in San Francisco, USA, and he developed and implemented an integrated Research and Early Development (RED) Neuroscience strategy for the Beerse, Belgium site as Chief Medical Officer, Johnson & Johnson Pharmaceutical R&D, RED EU. From 2003 to 2007, Stef served as Site Head, Vice President of Development and Chairman of the Development Management Committee for Tibotec, based in Mechelen, Belgium. During his tenure, two of the company's HIV medicines were granted accelerated approval.

Before joining Tibotec, Stef was Vice President, Development & Regulatory Affairs at Crucell in Leiden, the Netherlands, and held several senior positions within Janssen including Vice President, Global Regulatory Affairs and Pharmacovigilance, and Vice President, Medical Affairs for the Europe, Middle East and Africa (EMEA) region. He joined the Janssen Research Foundation in 1987 and led the global clinical development of RISPERDAL, one of the most successful Janssen antipsychotic medicines.

Stef obtained his M.D. at the University of Leuven, Belgium, and the Prince Leopold Institute for Tropical Medicine in Antwerp, Belgium. He is a 1993 recipient of the Dr. Paul Janssen Award for R&D and a 1998 recipient of the Johnson Medal for R&D.